ESMO News

October 22, 2020

CodeBreak 100: results show durability of clinical benefit with sotorasib in patients with non-small cell lung cancer

Durability of clinical benefit and biomarkers in patients with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). CodeBreaK 100 is an important, multicenter, […]
October 20, 2020

5-year follow-up data from the SOLO-1 trial with analysis of the information up to March 5, 2020 were highlighted at ESMO 2020

The efficacy of olaparib as maintenance therapy in newly diagnosed advanced ovarian cancer with BRCA mutation: 5-year follow-up from SOLO-1 trial Patients with newly diagnosed advanced […]